<DOC>
	<DOC>NCT02104245</DOC>
	<brief_summary>This study (ARD-3150-1201, ORBIT-4) will evaluate the safety and efficacy of inhaled Pulmaquin compared to inhaled placebo in subjects who have a confirmed diagnosis of non-cystic fibrosis (non-CF) bronchiectasis with a history of pulmonary exacerbations and chronic P. aeruginosa infections.</brief_summary>
	<brief_title>Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis</brief_title>
	<detailed_description>This is a multinational, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Pulmaquin compared to placebo in the management of chronic lung infections with P. aeruginosa in subjects with non-CF bronchiectasis with a history of pulmonary exacerbations. This study will consist of a Screening Phase, a Double-Blind Phase (6 cycles each consisting of 28-days once daily Pulmaquin or Placebo, and 28 days off treatment) followed by Open-Label Extension (28 days on Pulmaquin).</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Confirmed diagnosis of nonCF bronchiectasis History of P. aeruginosa respiratory infections At least two pulmonary exacerbations treated with antibiotics in the previous year Have a clinical diagnosis of CF Are pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non Cystic Fibrosis Bronchiectasis, Pulmaquin, Ciprofloxacin, Pseudomonas aeruginosa</keyword>
</DOC>